|Titre :||Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis (2021)|
|Auteurs :||A. BAHJI ; A. C. MEYYAPPAN ; E. R. HAWKEN ; P. G. TIBBO|
|Type de document :||Article : Périodique|
|Dans :||International Journal of Drug Policy (Vol.97, November 2021)|
|Article en page(s) :||art. 103295|
|Note générale :||Response: Danilewitz M. Emerging pharmacological treatments for cannabis use disorder. International Journal of Drug Policy, 2022, Vol. 110, art. 103850. https://doi.org/10.1016/j.drugpo.2022.103850|
|Discipline :||TRA (Traitement et prise en charge / Treatment and care)|
Thésaurus TOXIBASECANNABIS ; PHARMACOTHERAPIE ; CANNABINOIDES ; EFFICACITE ; COMPARAISON ; TRAITEMENT ; MEDICAMENTS ; EFFET SECONDAIRE
Objective: This study aimed to determine the efficacy and acceptability of pharmacotherapies for cannabis use disorder (CUD).
Methods: We conducted a systematic review and frequentist network meta-analysis, searching five electronic databases for randomized placebo-controlled trials of individuals diagnosed with CUD receiving pharmacotherapy with or without concomitant psychotherapy. Primary outcomes were the reduction in cannabis use and retention in treatment. Secondary outcomes were adverse events, discontinuation due to adverse events, total abstinence, withdrawal symptoms, cravings, and CUD severity. We applied a frequentist, random-effects Network Meta-Analysis model to pool effect sizes across trials using standardized mean differences (SMD, g) and rate ratios (RR) with their 95% confidence intervals.
Results: We identified a total of 24 trials (n=1912, 74.9% male, mean age 30.2 years). Nabilone (d=-4.47 [-8.15; -0.79]), topiramate (d=-3.80 [-7.06; -0.54]), and fatty-acid amyl hydroxylase inhibitors (d=-2.30 [-4.75; 0.15]) reduced cannabis use relative to placebo. Dronabinol improved retention in treatment (RR=1.27 [1.02; 1.57]), while topiramate worsened treatment retention (RR=0.62 [0.42; 0.91]). Gabapentin reduced cannabis cravings (d=-2.42 [-3.53; -1.32], while vilazodone worsened craving severity (d=1.69 [0.71; 2.66]. Buspirone (RR=1.14 [1.00; 1.29]), venlafaxine (RR=1.78 [1.40; 2.26]), and topiramate (RR=9.10 [1.27; 65.11]) caused more adverse events, while topiramate caused more dropouts due to adverse events.
Conclusions: Based on this review, some medications appeared to show promise for treating individual aspects of CUD. However, there is a lack of robust evidence to support any particular pharmacological treatment. There is a need for additional studies to expand the evidence base for CUD pharmacotherapy. While medication strategies may become an integral component for CUD treatment one day, psychosocial interventions should remain the first line given the limitations in the available evidence.
|Domaine :||Drogues illicites / Illicit drugs|
|Sous-type de document :||Méta-analyse / Meta-analysis ; Revue de la littérature / Literature review|
|Affiliation :||Department of Psychiatry, University of Calgary, Calgary, AB, Canada|